Pay in 4 interest-free payments of $5.10 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
16 Ludvik, B., et al., Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial
Hamburger, D
To help minimize side effects, both medications start at the lowest dose and gradually increase over several weeks
However, the substantially better efficacy (concerning HbA 1c and BW reductions) compared to semaglutide at the standard dose used in most type 2 T2D trials was the most remarkable finding (85, 86)
US$ 25.31
US$ 28.96
US$ 20.67
US$ 22.16
US$ 23.46
US$ 29.31
US$ 29.70
